A proposed model using glycation metrics and circulating biomarkers for the prevention of cardiovascular disease
- PMID: 40873802
- PMCID: PMC12378529
- DOI: 10.3389/fmed.2025.1624682
A proposed model using glycation metrics and circulating biomarkers for the prevention of cardiovascular disease
Abstract
Introduction: Cardiovascular aging starts early in life due to the glycation of critical proteins, though its progression remains undetected in the formative years. The glycation reaction affects all tissues by the same non enzymatic irreversible reaction. The variables are the pH, temperature, glucose concentration, and the specific protein. This relationship implies that glycated blood biomarkers could potentially be used as a proxy for assessing in situ myocardial changes.
Methods: Laboratory tests for troponin I (cTnI), hemoglobin A1c (A1c), fructosamine, and low-density lipoprotein (LDL), were chosen to calculate the proxy for in situ glycation. An algorithm was developed incorporating these variables as individual measurements and as calculated metrics of glycation. This data was obtained from previous large group studies of variables and outcomes.
Results: Modeling of glycation was determined for each variable. Using metrics from multiple studies, theoretical rates of glycation of LDL and troponin I were calculated. The glycated changes in LDL and troponin I were used to determine the increases above optimal physiological rates.
Conclusion: Laboratory results of LDL, cTnI, A1c and fructosamine could be used sequentially to derive a cost-effective proxy for assessing in situ aging and deterioration of cardiovascular tissue. This model could theoretically predict the rate of cardiovascular aging by integrating four blood biomarkers into a dedicated algorithm guiding proactive diagnostics and treatment.
Keywords: algorithm; biomarkers; cardiovascular disease; glycation; prevention.
Copyright © 2025 Valk and McMorrow.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes.Cochrane Database Syst Rev. 2023 May 31;5(5):CD014513. doi: 10.1002/14651858.CD014513. Cochrane Database Syst Rev. 2023. PMID: 37254718 Free PMC article.
-
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.Alzheimers Dement. 2021 Apr;17(4):704-715. doi: 10.1002/alz.12215. Epub 2021 Jan 21. Alzheimers Dement. 2021. PMID: 33480172 Free PMC article.
-
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21. Clin Orthop Relat Res. 2025. PMID: 38905450
References
-
- Parmley WW. Prevalence and clinical significance of silent myocardial ischemia. Circulation. (1989) 80:IV68–73. - PubMed
-
- Zhang ZM, Rautaharju PM, Prineas RJ, Rodriguez CJ, Loehr L, Rosamond WD, et al. Race and sex differences in the incidence and prognostic significance of silent myocardial infarction in the atherosclerosis risk in communities (ARIC) study. Circulation. (2016) 133:2141–8. doi: 10.1161/CIRCULATIONAHA.115.021177, PMID: - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials